[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-390477-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-390477-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","boostrix-highlights-of-prescribing-information","BOOSTRIX - Highlights of Prescribing Information","","BOOSTRIX prescribing highlights summarize safety and clinical use of the tetanus, reduced diphtheria, and acellular pertussis (Tdap) vaccine. It supports active booster immunization for individuals aged 10 years and older and vaccination during the third trimester of pregnancy to protect infants under 2 months. The document outlines intramuscular dosing (0.5 mL), timing after prior DTaP/Td/Tdap doses, and considerations for tetanus-prone wound management, with key contraindications, warnings about neurologic conditions, and common adverse reactions by age group.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/boostrix-highlights-of-prescribing-information/390477/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/boostrix-highlights-of-prescribing-information/390477.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-25",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What conditions does BOOSTRIX treat for vaccination use?","Question",{"text":63,"@type":64},"BOOSTRIX is indicated for active booster immunization against tetanus, diphtheria, and pertussis for people aged 10 years and older, and for immunization during the third trimester of pregnancy to prevent pertussis in infants younger than 2 months.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is BOOSTRIX dosed and scheduled?",{"text":68,"@type":64},"BOOSTRIX is given intramuscularly, with each dose of 0.5 mL. An initial dose is administered 5 years or more after the last DTaP series dose or after a Td dose, and additional dosing guidance is provided for at least 9 years after the initial dose of a prior Tdap.",{"name":70,"@type":61,"acceptedAnswer":71},"What are key contraindications and major warnings?",{"text":72,"@type":64},"Contraindications include severe allergic reaction to prior tetanus/diphtheria/pertussis vaccine components and encephalopathy within 7 days after a previous pertussis-containing vaccine. Warnings include increased risk of Guillain-Barré syndrome with tetanus toxoid-containing vaccines in certain prior cases and reasons to defer vaccination for progressive or unstable neurologic conditions.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},390477,1790468072,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","HIGHLIGHTS OF PRESCRIBING INFORMATION  \nThese highlights do not include all the information needed to use BOOSTRIX safely and effectively. See full prescribing information for  \nBOOSTRIX.  \nBOOSTRIX (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular  \nPertussis Vaccine, Adsorbed) injectable suspension, for intramuscular use Initial U.S. Approval: 2005  \n-----------------------------INDICATIONS AND USAGE----------------------------  \nBOOSTRIX is a vaccine indicated for:  \n• active booster immunization against tetanus, diphtheria, and pertussis in individuals aged 10 years and older,(1)  \n• immunization during the third trimester of pregnancy to prevent pertussis in infants younger than 2 months of age. (1)  \n-------------------------DOSAGE AND ADMINISTRATION-----------------------  \nFor intramuscular use. (2)  \n• Each dose of BOOSTRIX is 0.5 mL. (2.2)  \n• An initial dose of BOOSTRIX is administered 5 years or more after the last dose of the Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) series or 5 years or more after a dose of Tetanus and Diphtheria Toxoids Adsorbed (Td). BOOSTRIX may be administered as an additional dose 9 years or more after the initial dose of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap) . (2.2)  \n• BOOSTRIX may be administered for tetanus prophylaxis for wound  \nmanagement. For management of a tetanus-prone wound, a dose of BOOSTRIX may be administered ifat least 5 years have elapsed since previous receipt of a tetanus toxoid-containing vaccine. (2.2)  \n• To provide protection against pertussis in infants younger than 2 months of age, administer BOOSTRIX during the third trimester of pregnancy.(2.2)  \n-----------------------DOSAGE FORMS AND STRENGTHS----------------------  \nInjectable suspension. Each dose is 0.5 mL. (3)  \n-------------------------------CONTRAINDICATIONS------------------------------  \n• Severe allergic reaction (e.g., anaphylaxis) after a previous dose of any tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine or to any component of BOOSTRIX. (4.1)  \n• Encephalopathy within 7 days of administration of a previous pertussis antigen-containing vaccine. (4.2)  \n------------------------WARNINGS AND PRECAUTIONS-----------------------  \n• If Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the risk of Guillain-Barré syndrome may be increased following a subsequent dose of tetanus  \ntoxoid-containing vaccine, including BOOSTRIX. (5.2)  \n• Progressive or unstable neurologic conditions are reasons to defer vaccination with a pertussis-containing vaccine, including BOOSTRIX.(5.3)  \n• Persons who experienced an Arthus-type hypersensitivity reaction following a prior dose of a tetanus toxoid-containing vaccine should not receive BOOSTRIX unless at least 10 years have elapsed since the last dose of a tetanus toxoid-containing vaccine. (5.4)  \n-------------------------------ADVERSE REACTIONS------------------------------  \n• Common solicited adverse reactions (≥15%) in adolescents (aged 10 to 18 years) were pain, redness, and swelling at the injection site; increase in arm circumference of the injected arm; headache; fatigue; and gastrointestinal symptoms. (6.1)  \n• Common solicited adverse reactions (≥15%) in adults (aged 19 to  \n64 years) were pain, redness, and swelling at the injection site; headache; fatigue; and gastrointestinal symptoms. (6.1)  \n• The most common solicited adverse reaction (≥15%) in the elderly (aged 65 years and older) was pain at the injection site. (6.1)  \nTo report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or VAERS at 1-800-822-7967 or [www.vaers.hhs.gov](www.vaers.hhs.gov).  \nSee 17 for PATIENT COUNSELING INFORMATION.  \nRevised: 7/2026  \n\n| FULL PRESCRIBING INFORMATION: CONTENTS*\u003Cbr>1 INDICATIONS AND USAGE\u003Cbr>2 DOSAGE AND ADMINISTRATION\u003Cbr>2.1 Preparation for Administration\u003Cbr>2.2 Administration, Dose,","cbCaisPbQUpxE2zn","https://ap.wps.com/l/cbCaisPbQUpxE2zn","pdf",512809,34,"English","# Indications and Usage\n# Dosage and Administration\n## Preparation for Administration\n## Administration, Dose, and Schedule\n## Additional Dosing Information\n# Dosage Forms and Strengths\n# Contraindications\n# Warnings and Precautions\n# Adverse Reactions\n# Use in Specific Populations","[{\"question\":\"What conditions does BOOSTRIX treat for vaccination use?\",\"answer\":\"BOOSTRIX is indicated for active booster immunization against tetanus, diphtheria, and pertussis for people aged 10 years and older, and for immunization during the third trimester of pregnancy to prevent pertussis in infants younger than 2 months.\"},{\"question\":\"How is BOOSTRIX dosed and scheduled?\",\"answer\":\"BOOSTRIX is given intramuscularly, with each dose of 0.5 mL. An initial dose is administered 5 years or more after the last DTaP series dose or after a Td dose, and additional dosing guidance is provided for at least 9 years after the initial dose of a prior Tdap.\"},{\"question\":\"What are key contraindications and major warnings?\",\"answer\":\"Contraindications include severe allergic reaction to prior tetanus/diphtheria/pertussis vaccine components and encephalopathy within 7 days after a previous pertussis-containing vaccine. Warnings include increased risk of Guillain-Barré syndrome with tetanus toxoid-containing vaccines in certain prior cases and reasons to defer vaccination for progressive or unstable neurologic conditions.\"}]","BOOSTRIX - Highlights of Prescribing Information | PDF",1790334883,86]